Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 Slide Shows
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
CES 2010 Coverage 

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

Font Down Font Up

 
Biovail Turns To Profit In Q2 - Update
8/6/2009 11:02 AM  ET
RELATED NEWS
Biovail Says Teva's Proposed Generic Wellbutrin XL Trial Too Small And Too Brief
Biovail Corp. Has Risen To A New High For The Year
Biovail Corp To Present At JPMorgan Healthcare Conference; Webcast At 2:00 PM ET

Trade BVF now with
TOP MARKET NEWS
Obama Meets With House And Senate Leaders In Effort To Boost Bipartisanship
Opel/Vauxhall Unveils €11 Bln Investment Plan; To Cut 8,300 Jobs
Stocks Building On Strong Gains In Early Afternoon Trading - U.S. Commentary
House GOP Leaders Demand White House Scrap Health Reform Legislation Prior To Summit
Stocks Give Back Ground But Remain Mostly Higher - U.S. Commentary
(RTTNews) -  Thursday, specialty pharmaceutical company Biovail Corporation (BVF: News ,BVF.TO: News ) reported a profit for the second quarter compared with a loss last year, helped mainly by higher revenue and lower restructuring costs.

For the quarter, net income was $24.09 million or $0.15 per share, compared with a loss of $25.29 million or $0.16 per share in the same quarter last year.

Special items had a $0.19 per share impact on second quarter net income, much lower than last year's $0.53 per share impact.

Second quarter results include, among other special items, $30.4 million related to the collaboration agreement with ACADIA Pharmaceuticals, Inc. for pimavanserin and $11.4 million in restructuring costs. On the other hand, the prior-year quarter results included, among other items, $51.8 million charge related to the closure of facilities and a charge of $24.6 million related to an agreement with the U.S. Attorney's Office for the District of Massachusetts related to their investigation into the 2003 commercial launch of Cardizem LA.

On an average, seven analysts polled by Thomson Reuters expected the company to report earnings of $0.34 per share for the quarter. Analysts' estimates typically exclude special items.

Toronto, Canada-based Biovail's total revenue for the quarter was $193.54 million, up from $186.10 million in the comparable quarter last year. Analysts expected the company to report revenue of $190.71 million.
Product sales increased 7% to $187.72 million from $175.67 million, helped by higher revenues from Wellbutrin XL and the inclusion of revenues from Xenazine/Nitoman and Aplenzin.

Research and development revenue was $3.26 million, lower than $5.70 million a year ago, due to lower volumes of clinical research and laboratory testing services provided to external customers, as well as negative impact of the weakening of the Canadian dollar against the U.S. dollar.

Royalty and other revenue declined to $2.56 million from $4.73 million last year, reflecting lower revenue based on sales of fenofibrate tablets.

Cash earnings for the quarter was $0.59 per share, up from $0.44 per share in the year-ago quarter. Excluding specific items, the company reported cash earnings of $0.50 per share for the quarter.

For the six month period, net income surged to $63.09 million or $0.40 per share from $31.09 million or $0.19 per share in the prior-year period. Year-to-date, revenue was $366.85 million, lower than $394.59 million last year.

To receive FREE breaking news email alerts for Biovail Corp and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print           Follow Us RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

     
 

More Breaking News-US

79  ATA Automation Q3 Profit Declines - Update
78  Triple-S Management Q4 Profit Up, Tops View - Update
77  Microsoft, Interpublic Group In Ad-server Solution Deal - Update
76  Stepan Q4 Profit Surges - Update
75  Centene Q4 Profit Up - Update
74  Delta Responds To Japan Airlines Decision To Stay With American - Update
73  American Commercial Lines Q4 Profit Down - Update
72  OJSC VimpelCom Board Recommends Exchange Offer By VimpelCom Ltd - Update
71  American Airlines Says It Is Pleased With Japan Airlines' Continuing Membership In Oneworld Alliance - Update
70  Nabors Industries Expects Q4 Above Street Estimates - Update
69  RiskMetrics Swings To Q4 Profit - Update
68  Potlatch Swings To Profit In Q4, Yet FFO Declines - Update
67  Sanofi-aventis Completes Tender Offer For Chattem - Update
66  Gartner Q4 Profit Declines, Yet Beats Estimate; Guides FY10 - Update
65  Alpha Natural Q4 Profit Rises - Update
  

 

Copyright © 2010 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service| How To Use RTTNews.com| Advertise| Privacy| Buy Content | RSS